O	0	13	Participation	Participation	NN	B-NP
O	14	16	of	of	IN	B-PP
O	17	20	p53	p53	NN	B-NP
B-Cell	21	29	cellular	cellular	JJ	I-NP
B-Cancer	30	36	tumour	tumour	NN	I-NP
O	37	44	antigen	antigen	NN	I-NP
O	45	47	in	in	IN	B-PP
O	48	62	transformation	transformation	NN	B-NP
O	63	65	of	of	IN	B-PP
O	66	72	normal	normal	JJ	B-NP
B-Cell	73	82	embryonic	embryonic	JJ	I-NP
I-Cell	83	88	cells	cell	NNS	I-NP
O	88	89	.	.	.	O

O	91	94	The	The	DT	B-NP
B-Cell	95	103	cellular	cellular	JJ	I-NP
B-Cancer	104	110	tumour	tumour	NN	I-NP
O	111	118	antigen	antigen	NN	I-NP
O	119	122	p53	p53	NN	I-NP
O	123	125	is	be	VBZ	B-VP
O	126	131	found	find	VBN	I-VP
O	132	134	at	at	IN	B-PP
O	135	143	elevated	elevated	JJ	B-NP
O	144	150	levels	level	NNS	I-NP
O	151	153	in	in	IN	B-PP
O	154	155	a	a	DT	B-NP
O	156	160	wide	wide	JJ	I-NP
O	161	168	variety	variety	NN	I-NP
O	169	171	of	of	IN	B-PP
O	172	183	transformed	transform	VBN	B-NP
B-Cell	184	189	cells	cell	NNS	I-NP
O	190	191	(	(	(	O
O	191	194	for	for	IN	B-PP
O	195	202	reviews	review	NNS	B-NP
O	203	206	see	see	VBP	B-VP
O	207	211	refs	ref	NNS	B-NP
O	212	213	1	1	CD	I-NP
O	213	214	,	,	,	I-NP
O	215	216	2	2	CD	I-NP
O	216	217	)	)	)	O
O	217	218	.	.	.	O

O	219	223	Very	Very	RB	B-NP
O	224	230	little	little	JJ	I-NP
O	231	233	is	be	VBZ	B-VP
O	234	237	yet	yet	RB	I-VP
O	238	243	known	know	VBN	I-VP
O	244	249	about	about	IN	B-PP
O	250	253	the	the	DT	B-NP
O	254	261	precise	precise	JJ	I-NP
O	262	274	relationship	relationship	NN	I-NP
O	275	277	of	of	IN	B-PP
O	278	281	p53	p53	NN	B-NP
O	282	284	to	to	TO	B-PP
O	285	294	malignant	malignant	JJ	B-NP
O	295	309	transformation	transformation	NN	I-NP
O	309	310	.	.	.	O

O	311	319	Although	Although	IN	B-SBAR
O	320	323	the	the	DT	B-NP
O	324	332	increase	increase	NN	I-NP
O	333	335	in	in	IN	B-PP
O	336	339	p53	p53	NN	B-NP
O	340	346	levels	level	NNS	I-NP
O	347	352	could	could	MD	B-VP
O	353	355	be	be	VB	I-VP
O	356	357	a	a	DT	B-NP
O	358	367	secondary	secondary	JJ	I-NP
O	368	370	by	by	IN	B-PP
O	370	371	-	-	HYPH	B-NP
O	371	378	product	product	NN	I-NP
O	379	381	of	of	IN	B-PP
O	382	385	the	the	DT	B-NP
O	386	397	transformed	transform	VBN	I-NP
O	398	403	state	state	NN	I-NP
O	403	404	,	,	,	O
O	405	407	it	it	PRP	B-NP
O	408	410	is	be	VBZ	B-VP
O	411	418	equally	equally	RB	B-ADJP
O	419	427	possible	possible	JJ	I-ADJP
O	428	432	that	that	IN	B-SBAR
O	433	436	p53	p53	NN	B-NP
O	437	439	is	be	VBZ	B-VP
O	440	448	actively	actively	RB	I-VP
O	449	457	involved	involve	VBN	I-VP
O	458	460	in	in	IN	B-PP
O	461	469	altering	alter	VBG	B-VP
B-Cell	470	478	cellular	cellular	JJ	B-NP
O	479	485	growth	growth	NN	I-NP
O	486	496	properties	property	NNS	I-NP
O	496	497	,	,	,	O
O	498	508	especially	especially	RB	B-ADVP
O	509	511	as	as	IN	B-SBAR
O	512	514	it	it	PRP	B-NP
O	515	518	has	have	VBZ	B-VP
O	519	523	been	be	VBN	I-VP
O	524	534	implicated	implicate	VBN	I-VP
O	535	537	in	in	IN	B-PP
O	538	541	the	the	DT	B-NP
O	542	552	regulation	regulation	NN	I-NP
O	553	555	of	of	IN	B-PP
O	556	562	normal	normal	JJ	B-NP
B-Cell	563	567	cell	cell	NN	I-NP
O	568	581	proliferation	proliferation	NN	I-NP
O	581	582	.	.	.	O

O	583	585	We	We	PRP	B-NP
O	586	592	sought	seek	VBD	B-VP
O	593	595	to	to	TO	I-VP
O	596	600	test	test	VB	I-VP
O	601	608	whether	whether	IN	B-SBAR
O	609	612	p53	p53	NN	B-NP
O	613	618	could	could	MD	B-VP
O	619	625	behave	behave	VB	I-VP
O	626	628	in	in	IN	B-PP
O	629	630	a	a	DT	B-NP
O	631	637	manner	manner	NN	I-NP
O	638	645	similar	similar	JJ	B-ADJP
O	646	648	to	to	TO	B-PP
O	649	654	known	know	VBN	B-NP
O	655	660	genes	gene	NNS	I-NP
O	661	663	in	in	IN	B-PP
O	664	665	a	a	DT	B-NP
O	666	676	biological	biological	JJ	I-NP
O	677	681	test	test	NN	I-NP
O	682	688	system	system	NN	I-NP
O	688	689	,	,	,	O
O	690	693	and	and	CC	O
O	694	696	we	we	PRP	B-NP
O	697	708	demonstrate	demonstrate	VBP	B-VP
O	709	713	here	here	RB	B-ADVP
O	714	718	that	that	IN	B-SBAR
O	719	722	p53	p53	NN	B-NP
O	723	726	can	can	MD	B-VP
O	727	736	cooperate	cooperate	VB	I-VP
O	737	741	with	with	IN	B-PP
O	742	745	the	the	DT	B-NP
O	746	755	activated	activate	VBN	I-NP
O	756	758	Ha	Ha	NN	I-NP
O	758	759	-	-	HYPH	I-NP
O	759	762	ras	ras	NN	I-NP
O	763	771	oncogene	oncogene	NN	I-NP
O	772	774	to	to	TO	B-VP
O	775	784	transform	transform	VB	I-VP
O	785	791	normal	normal	JJ	B-NP
B-Cell	792	801	embryonic	embryonic	JJ	I-NP
I-Cell	802	807	cells	cell	NNS	I-NP
O	807	808	.	.	.	O

O	809	812	The	The	DT	B-NP
O	813	822	resultant	resultant	JJ	I-NP
B-Cell	823	827	foci	focus	NNS	I-NP
O	828	835	contain	contain	VBP	B-VP
B-Cell	836	841	cells	cell	NNS	B-NP
O	842	844	of	of	IN	B-PP
O	845	846	a	a	DT	B-NP
O	847	855	markedly	markedly	RB	I-NP
O	856	863	altered	alter	VBN	I-NP
O	864	874	morphology	morphology	NN	I-NP
O	875	880	which	which	WDT	B-NP
O	881	888	produce	produce	VBP	B-VP
O	889	893	high	high	JJ	B-NP
O	894	900	levels	level	NNS	I-NP
O	901	903	of	of	IN	B-PP
O	904	907	p53	p53	NN	B-NP
O	907	908	.	.	.	O

B-Cell	909	913	Cell	Cell	NN	B-NP
I-Cell	914	919	lines	line	NNS	I-NP
O	920	931	established	establish	VBN	B-VP
O	932	936	from	from	IN	B-PP
O	937	941	such	such	JJ	B-NP
B-Cell	942	946	foci	focus	NNS	I-NP
O	947	953	elicit	elicit	VBP	B-VP
B-Cancer	954	961	tumours	tumour	NNS	B-NP
O	962	964	in	in	IN	B-PP
O	965	974	syngeneic	syngeneic	JJ	B-NP
O	975	982	animals	animal	NNS	I-NP
O	982	983	.	.	.	O

